Lex­i­con bids farewell to top sell­er Xer­me­lo in re­or­ga­ni­za­tion to­ward R&D pipeline

Three years ago, Lex­i­con Phar­ma­ceu­ti­cals was fly­ing high fol­low­ing the FDA ap­proval and com­mer­cial launch of its Xer­me­lo drug, which treats car­ci­noid syn­drome di­ar­rhea …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER